Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Does docetaxel plus prednisone prolong the survival of men with metastatic hormone-refractory prostate cancer?

Nature Clinical Practice Oncology volume 2, pages 68–69 (2005)Cite this article

boxed-textTannock IF et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502–1512

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Tannock IF et al. (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomised trial with palliative end points. J Clin Oncol 14: 1756–1764

    Article  CAS  Google Scholar 

  2. Kantoff W et al. (1999) Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukaemia group B 9182 study. J Clin Oncol 17: 2506–2513

    Article  CAS  Google Scholar 

  3. Berry W et al. (2002) Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol 168: 2439–2443

    Article  CAS  Google Scholar 

  4. Muthuramalingam SR et al. (2004) Management of patients with hormone refractory prostate cancer. Clin Oncol 16: 505–516

    Article  CAS  Google Scholar 

  5. Oudard S et al. (2002) Preliminary results of a phase II randomised trial of docetaxel (D), estramustine (E) and prednisone (P) – two schedules – versus mitoxantrone (M) and prednisone in patients (pts) with hormone refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 21: a706

    Google Scholar 

  6. Petrylak DP et al. (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513–1520

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Suzanne Farley, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Consultant Medical Oncologist at the Cancer Research UK Department of Medical Oncology at the Churchill Hospital, Oxford

    Andrew Protheroe

Authors
  1. Andrew Protheroe
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Protheroe, A. Does docetaxel plus prednisone prolong the survival of men with metastatic hormone-refractory prostate cancer?. Nat Rev Clin Oncol 2, 68–69 (2005). https://doi.org/10.1038/ncponc0080

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0080

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing